Xin Lang Cai Jing·2026-02-03 02:31Group 1 - The company is in a value realization phase, leveraging its technology platforms such as sustained-release microspheres, antibody drugs, and recombinant protein vaccines for product iteration and comprehensive layout in key areas like digestive tract, assisted reproduction, and mental health [1] - Multiple drugs are at various research stages, with the monoclonal antibody Lakanqita already submitted for market approval for moderate to severe psoriasis and included in the priority review process, showing significant clinical value [1] - The company plans to acquire 64.81% of Vietnam's IMP Company by May 2025, which is expected to enhance its global commercialization strategy [1] Group 2 - Revenue forecasts for the company from 2025 to 2027 are projected at 11.977 billion, 12.028 billion, and 12.996 billion yuan, with year-on-year growth rates of 1.4%, 0.4%, and 8.1% respectively [2] - Net profit attributable to shareholders is expected to be 2.173 billion, 2.227 billion, and 2.528 billion yuan for the same period, with growth rates of 5.4%, 2.5%, and 13.5% respectively [2] - The company is rated as "overweight" with corresponding PE ratios of 14.3, 13.9, and 12.3 times based on the closing price on January 30 [2]